- Home
- JLL vs SNN Comparison
JLL vs SNN Comparison
Compare JLL & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLL | SNN |
|---|---|---|
| Founded | 1997 | 1856 |
| Country | United States | United Kingdom |
| Employees | 48000 | 16988 |
| Industry | Real Estate | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 14.3B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | JLL | SNN |
|---|---|---|
| Price | $294.98 | $30.09 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $365.33 | $36.25 |
| AVG Volume (30 Days) | 344.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 03-16-2026 |
| Dividend Yield | N/A | ★ 2.48% |
| EPS Growth | ★ 45.13 | N/A |
| EPS | ★ 3.33 | N/A |
| Revenue | ★ $26,115,600,000.00 | N/A |
| Revenue This Year | $7.71 | $8.58 |
| Revenue Next Year | $6.99 | $5.60 |
| P/E Ratio | $88.78 | ★ $64.97 |
| Revenue Growth | ★ 11.45 | N/A |
| 52 Week Low | $238.12 | $29.08 |
| 52 Week High | $363.06 | $38.79 |
Technical Indicators
Market Signals| Indicator | JLL | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 44.71 |
| Support Level | $290.42 | $29.10 |
| Resistance Level | $310.38 | $31.28 |
| Average True Range (ATR) | 10.00 | 0.49 |
| MACD | 1.53 | 0.03 |
| Stochastic Oscillator | 54.66 | 42.11 |
Price Performance
Historical ComparisonAbout JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $86 billion for clients across diverse public and private real estate strategies as of the end of 2025.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.